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Background: Metastatic breast cancer is a major cause of death among women worldwide; therefore efficient
therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based
combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic
breast cancer.
Methods: 2×108 particles of a Semliki Forest virus vector expressing interleukin-12 (SFV-IL-12) and/or 2×107 units of an
aroC− Samonella Typhimurium strain (LVR01) were injected into 4T1 tumor nodules orthotopically implanted in mice.
Tumors were surgically resected and long-term survival was determined. IL-12 and interferon-γ were quantified by
Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung
metastasis was calculated with a clonogenic assay.
Results: SFV-IL-12 and LVR01 timely inoculated and followed by surgical resection of tumors succeeded in complete
inhibition of lethal lung metastasis and long-term survival in 90 % of treated mice. The combined therapy was markedly
synergistic compared to each treatment alone, since SFV-IL-12 monotherapy showed a potent antiangiogenic effect, being
able to inhibit tumor growth and extend survival, but could not prevent establishment of distant metastasis and death of
tumor-excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential,
despite its ability to invade breast cancer cells and induce granulocyte recruitment. The efficacy of the combined therapy
depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed
when SFV-IL-12 was administered previous to LVR01, whereas administration of LVR01 before SFV-IL-12 had negligible
antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress SFV-IL-12 antiangiogenic effects associated to
lower IL-12 expression in this group. Re-challenged mice were unable to reject a second 4T1 tumor; however 100 % of
them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the
most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model.
Conclusions: SFV-IL-12-based gene therapy combined with Salmonella LVR01 neoadjuvant administration has a
synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory
metastasis in locally advanced breast cancer.* Correspondence: mgkramer@higiene.edu.uy
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Metastatic breast cancer (MBC), including locally ad-
vanced breast cancer (LABC) and distant relapse (DR)
are, nowadays, major challenges to oncologists, and to
researchers focused on the development of new treat-
ments against these deadly disease situations. Despite
advances in early diagnosis and multidisciplinary thera-
peutic approaches, MBC remains incurable and current
main therapies goals range from symptoms palliation to
extending survival [1]. In severe cases of LABC, where
an underlying invasive disease is often present at the
time of diagnosis, neoadjuvant therapies (i.e., administra-
tion of therapeutic agents before a main treatment such
as mastectomy and/or radiotherapy) are first-line choices
[2–4]. Presently, such neoadjuvant therapies relay mostly
on cytotoxic chemotherapies which, unfortunately, have
limited efficacy, as well as multiple toxic effects. It is,
therefore, extremely necessary the development of alter-
native therapeutic strategies that are more effective
against MBC and that can be applicable in neoadjuvancy
to treat LABC. In addition, it is also equally important
that the new therapeutic approaches are evaluated in
clinically relevant animal models of breast cancer.
The murine 4T1 orthotopic model mimics aggressive
types of breast cancer since it is rapidly progressive,
highly angiogenic and angioinvasive and metastasizes
spontaneously from little primary tumors to draining
lymph nodes and distant organs, following a metastatic
pattern that closely resembles the human counterpart
[5–7]. In addition, the carcinogenesis dynamics of 4T1
tumors established in immunocompetent BALB/c mice
is comparable to human stage IV type of breast cancer
[8]. Moreover, and analogously to human breast cancer,
4T1-derived tumors are poorly immunogenic [6]. In this
regard, several mechanistic studies have described the
cellular, molecular and soluble tumor-associated and
immune-related factors that participate in inhibiting the
host immunosurveillance effectors [9–11], making the
4T1 model particularly challenging for evaluating novel
strategies aimed at inducing an efficient antitumor im-
mune response. For all these reasons, the investigation
and discovery of effective neoadjuvant immunotherapies
against the metastatic disease in the murine 4T1 breast
cancer model could be of great clinical value.
Gene therapy is a relatively new paradigm in medicine
with enormous therapeutic potential. Actually, almost
2000 gene therapy clinical trials (most of them for can-
cer applications) were registered worldwide, having 96
trials already reached phases II/III to IV, indicating the
progress being made with respect to bringing gene ther-
apy closer to the clinical setting [12]. A number of dif-
ferent vectors and delivery systems have been applied;
however, viral vectors remain by far the most versatile,
popular and effective approach, been used in approximatelytwo-thirds of such clinical trials [13]. We have recently
shown that a gene therapy strategy based on the short-
term intratumoral (i.t) expression of the potent pro-
inflamatory cytokine interleukin-12 (IL-12) expressed
from a cytopathic Semliki Forest virus vector (SFV-IL-12)
inhibits tumor growth and extends survival in a transgenic
mice model of hepatocellular carcinoma (HCC) [14].
Moreover, this vector was also efficient in reducing tumor
volume and inducing T cell-mediated responses against
HCC spontaneously developed in woodchucks chronically
infected with an hepadnavirus very similar to hepatitis B
virus, a situation that closely resembles HCC disease in
humans [15]. In addition, SFV-IL-12 was proven to have a
stronger antitumor potential compared to other viral and
non-viral-based IL-12 expression systems in vivo due to
the strong SFV-mediated induction of apoptosis and acti-
vation of type-I interferon responses specifically in the
tumor [14, 16, 17]. When searching whether the thera-
peutic spectrum of this vector was expanded to breast
cancer, we found only one previous report where a similar
SFV-IL-12 construct was tested in the 4T1 model. There,
a significant reduction in primary tumor size as well as in
the percentage and number of lung metastases was ob-
served after several i.t. administrations of high amounts of
vector [18]. However, no information was provided about
long-term survival (i.e, at least 6 months after treatment)
and/or anti-metastatic effect of the therapy in tumor-
excised mice, which would be a more clinically relevant
condition, due to the fact that, in general, patients have
their primary tumor surgically removed.
On the other hand, bacteria-based therapies are a mo-
dality of increasing interest in anticancer immunothera-
peutic research due to the capability of many auxotrophic
mutants to restrict their growth to the rich nutrient milieu
tumor interior, inducing cell destruction and liberation of
tumor antigens, as well as in situ inflammation, triggering
a versatile immune response upon bacterial infection
[19–21]. It has also been shown that facultative anaerobic
bacteria, like attenuated Salmonella enterica serovar
Typhimurium (S. Typhimurium) and genetically modi-
fied Escherichia coli strains, elicit antitumor potential
against breast cancer models, especially if combined with
plasmids that express cytotoxic inducing factors or
immunostimulatory cytokines [22–26]. However, simi-
larly as for IL-12-based gene therapies, these studies were
mostly focused on evaluating the antitumor effect of bac-
teria against primary tumors; and so far there are no data
reporting complete remission of 4T1 primary tumors or
total inhibition of lung metastasis in operated mice.
Therefore, and in order to go a step forward towards a
possible clinical application of a gene- and bacteria-
based neoadjuvant therapy for MBC, we have evaluated
the anti-metastatic potential of the i.t. administration of
SFV-IL-12 and/or aroC− attenuated S. Typhimurium strain
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surgical resection. Our data showed a clear synergic an-
titumor effect of the combined therapy compared to
SFV-IL-12 and LVR01 monotherapies, achieving metastasis-
free and long-term survival in 90 % of treated animals.
Moreover, we observed that the efficacy of the combined
therapy radically depends on the order in which both
factors were administered; suggesting the existence of spe-
cific mechanisms underlying the observed synergic thera-
peutic effect.Methods
Cell lines and bacteria
Mouse breast carcinoma 4T1 cell line was obtained from
American Type Culture Collection (ATCC-CRL-2539™)
and grown in high Glucose (4.5 g/l) Dulbecco’s Modified
Eagle’s Medium (DMEM) with stable Glutamine, So-
dium Pyruvate and 3.7 g/l NaHCO3 (PAA Cell Culture
Company P04-04510) supplemented with 10 % Fetal
Bovine Serum (FBS, GE Healthcare). Chinese hamster
ovary cells CHO-K1 (ATCC- CCL-61™) used to produce
the viral vectors were cultured in F12K Medium (ATCC-
302004) supplemented with 10 % FBS. The BHK-21 cell
line (ATCC- CCL-10™) used to titer SFV-based vectors,
was cultured in Glasgow Minimum Essential Medium
(Invitrogen, Carlsbad, CA) supplemented with 5 % FBS.
All cell lines were grown at 37 °C in a humidified CO2
incubator and passaged when confluent using a 0.25 %
Trypsin 0.53 mM EDTA solution. The live attenuated
Salmonella strain employed in this study, LVR01, was
constructed earlier by introducing a null deletion into
the aroC gene of the parental canine S. Typhimurium
isolate, P228067 [27]. Bacteria cultures were grown at
37 °C in Luria-Bertani (LB) media shaking at 200-250 rpm
to OD600 = 1.5 and stored at -80 °C in 17 % glycerol stocks
until used.Viral vectors production
Recombinant SFV RNAs carrying IL-12 or lacZ genes
were amplified in vitro from pSFV-enhIL-12 [28] or
pSFV-LacZ [29] template plasmids, respectively, using
the SP6 DNA dependent RNA polymerase reaction and
co-electroporated into CHO-K1 cells with SFV-helper-
S2 and SFV-helper-C-S219A RNAs (which provided in
trans the envelope and capsid SFV proteins, respect-
ively), as described previously [30]. Electroporated cells
were incubated at 33 °C for 48 hs, supernatants were
collected and SFV viral particles (vp) were purified by
ultracentrifugation through a 20 % sucrose cushion at
100,000 g during 90 min. Titers of viral vector stocks
were determined in infected BHK-21 cells by indirect
immunofluorescence using a rabbit polyclonal antiserum
specific for the nsp2 subunit of SFV replicase as described[31]. Titers of 1.0x1011 for SFV-IL-12 and 1.2×1011 vp/ml
for SFV-LacZ were obtained.
Breast cancer model and treatments
All experimental procedures involving animals were ap-
proved and performed in accordance with our Univer-
sity’s Ethics Commission for Animal Experimentation
(CHEA, UdelaR). Six to 8 weeks old female BALB/c
mice (DILAVE, Uruguay) were inoculated in the 4th
right mammary fat pad with 70,000 4T1 cells resus-
pended in 50 μl phosphate saline buffer (PBS). Ten days
after cell implantation, 100 % mice showed palpable tu-
mors and were homogenously divided into the different
treatment groups. Fifty μl (in PBS) of the corresponding
treatments were injected into tumors using a sterile 1 ml
syringe with 27G needle. Tumor size was periodically
measured with a precision caliper and its volume was
calculated by the ellipsoid formulae (major diameter ×
minor diameter2 × 0.5). Surgical removal of tumors was
performed essentially as described [5, 8]. In addition, the
proximal draining lymph node was also carefully re-
moved along with the adjoining abdominal fat. Wounds
were closed using a sterile 19 mm 3/8 nylon monofila-
ment suture (HAD, China). Paracetamol (1 mg/ml) dis-
solved in drinking water was given to animals for 24 hs
to aid the post-operatory recovery. Survival was moni-
tored regularly, and animals were euthanized if found
moribund during the observation period. Dead mice
were autopsied to check for the presence of lung
metastasis.
Immunohistochemistry
Cryosections (5 μm thick) of tumors pre-infected with
2×107 cfu (colony forming units) were fixed with 4 %
paraformaldehyde (PFA), permeabilized with 0.2 %
Tween 20 in PBS and blocked with 1 % BSA in PBS
prior to staining using a specific rabbit anti-Salmonella
lipopolysaccharide (LPS) O Poly A antiserum (BD Biosci-
ences). Detection was performed with secondary goat
anti-rabbit Alexa Fluor® 555-conjugated antibody (Invitro-
gen). Cell membranes were stained using wheat germ ag-
glutinin (WGA) conjugated to Oregon Green® 488 or
Alexa Fluor® 350 (Life Technologies). The third channel of
fluorescence was occupied by 4’,6-diamidino-2-phenylin-
dole (DAPI, Invitrogen) or anti-Gr1 antibody conjugated
to Alexa Fluor® 488 (BD Biosciences) to detect cell nuclei
or granulocytes, respectively. Acquisition and processing
of images were carried out using a Nikon® Ti-S epifluores-
cence inverted microscope and analyzed with the NIS-
Elements software (Nikon).
Lungs metastasis
The number of 4T1 cells that reach the lungs during its
spontaneous metastatic process can be quantified by a
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ance to 6-thioguanine treatment [6, 7]. To this end, mice
were sacrified 35 days after tumor cells implantation,
lungs were isolated and finely minced with sterile scis-
sors and digested in a 5 ml PBS solution containing
20 mg Collagenase type I (230 u/mg, GIBCO™ 17100-
017) and 50 μg DNAseI (Sigma-Aldrich) for 1 h at 37 °C
on a rotating wheel. After incubation, 5 mM EDTA was
added to stop the enzymatic reaction and the tissue was
homogenized by pippeting several times. The homogen-
ate was washed in 10 ml PBS and samples were filtered
through a 70 μm Falcon cell strainer (BD Biosciences) to
obtain a clear solution. This solution was washed twice
in DMEM by 1500 rpm centrifugation at 4 °C. The cell
pellet was resuspended and serially diluted in 6-well tis-
sue culture plates containing DMEM supplemented with
10 % FBS and 1× Antibiotic/Antimycotic Solution
(Capricorn Scientific AAS-B) plus 60 μM 6-thioguanine
(Sigma Aldrich). Tumor cells formed foci within 10-14
days. Cell clones were fixed with PFA 4 % and stained
with 0.03 % methylene blue solution for macroscopic
counting. Resistant clonogenic metastasis were calcu-
lated on a per-organ basis as described [8].
Cytokine serum levels
Blood samples were obtained from the mice facial vein
and serum was recovered by centrifugation at 10,000 rpm
for 10 min and stored at -80 °C until protein measurement.
Murine IL-12 and IFN-γ levels were quantified by ELISA
(Enzyme-Linked ImmunoSorbent Assay) using Op-tEIA
Mouse IL-12 and IFN-γ Sets (BD Biosciences), respect-
ively, and according to the manufacturer’s instructions.
Statistical analysis
GraphPad Prism version 6.0 software was employed to
perform the statistical analyses. One way ANOVA was
used to assess the difference between groups in multiple
comparisons regarding one variable and Student’s t-test
was applied to evaluate the differences between selected
pair of groups. Survival curves obtained by the Kaplan-
Meyer method were statistically analyzed using the Log-
rank test. Data were considered significant when p values
were ≤0.05.
Results
Early lung metastases accompany 4T1 tumor growth and
could mimic LABC upon surgical resection of primary
tumors
Breast cancer aggressiveness and poor prognosis is com-
monly associated with metastasis occurrence to distant
organs, such as lungs, liver and bones. In this regard, it
is well known that early resection of primary tumors
contributes to control metastasis; however clinical outcome
depends on many factors, including growth dynamics andmetastatic characteristics of these tumors. In order to
correlate the 4T1 breast cancer model with clinical cases
of LABC in respect to its metastatic progression, we
evaluated the therapeutic impact of primary tumor re-
section at different time points. Small tumors (4-5 mm
diameter) could be homogeneously detected 10 days
after orthotopic implantation of 7×104 4T1 cells and by
day 16 tumors reached 6–7 mm diameter, still a feasible
surgically size. Thus, we defined days 10 and 16 post-
4T1 implantation as early and middle-early time points
for tumor resection, respectively. Control tumor-bearing
mice have a life span of 44 ± 5 days after 4T1 cells im-
plantation (Figs. 1 and 8b). Animals whose tumors were
surgically resected at day 10 showed an improved overall
survival (with 40 % mice surviving more than 6 months),
while 100 % animals operated at day 16 died at the same
rate as non-operated mice (Fig. 1a). In agreement with
these data, lung micro-metastatic cells were present at
day 10 in 40 % of the animals, while the rest were
metastasis-free; however, 6 days later (day 16), 100 % an-
imals presented a variable number (10-1300) of lung
micro-metastasis (Fig. 1b). Middle-early excised tumor
mice and non-operated controls showed comparable life
span and a similar amount of established lung metastasis
(in the order of 105 4T1 tumor cells/lungs) 35 days after
tumor implantation (Fig. 1b) suggesting that both facts
are associated. The autopsy of moribund mice revealed
in all cases the presence of numerous macroscopic
metastatic foci and a massive distortion of both lungs
(Fig. 1c), accompanied by severe breathing difficulties at
the time of death. These data confirmed the determinant
role of the metastatic disease in the survival outcome of
the 4T1 model of breast cancer [6]. In addition, non-
survivor animals occasionally presented visible meta-
static tumor nodules in liver, lymph nodes, spleen and/
or heart (not shown). It is important to note, that just a
small number of 4T1 metastatic cells (around 10–20,
Fig. 1b) are sufficient to progress to a severe lung meta-
static disease in the absence of primary tumors, indicat-
ing that these tumor cells may be particularly resistant
or indifferent to the host immune system in order to
persist. Due to the early metastatic dissemination and
their growing characteristics, we conclude that the 4T1-
tumor model could reflect most aggressive clinical cases
of LABC. Moreover, middle-early tumor-excised mice
would represent an excellent model of minimal residual
disease (MRD) for therapeutic intervention against
metastatic disease, since 100 % of animals develop lung
metastasis and do not survive in the long-term. Our data
also point out to a temporal window between days 10
and 16 (initiation - establishment of the metastatic
process) for evaluation of novel neoadjuvant strategies
(prior to surgical removal of primary tumors) aimed at
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Fig. 1 Effect of 4T1 breast cancer metastases in animals that
underwent tumor surgery. Tumor cells were orthotopically
implanted in mice mammary fat pads (day 0). Primary tumors were
left without surgery or removed by surgical excision, 10 or sixteen
(S-16) days later. a Kaplan–Meier plot shows the survival rate of the
indicated groups (n = 8). b Additional tumor-bearing or tumor
excised mice were sacrificed at 10, 16 or 35 days after 4T1 cells
inoculation, lungs were extracted and processed and the number of
lung metastases were quantified as described in Methods. 35 (S-16)
refers to a group of mice that underwent surgery at day 16 and
were checked for lung metastases 19 days later (i.e. 35 days after
4T1 tumor implantation). c Lungs extracted from a healthy control
mouse (Control) and from moribund mice showing numerous
metastatic nodules (Metastatic lungs). Non-significant (n.s.)
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growth, reduce angiogenesis and prolong survival in 4T1
tumor-bearing mice
We and other groups have shown that the amount of
IL-12 expressed at the tumor site using different viral
vectors is critical for tumor regression in a number of
cancer models [14–16, 18, 28, 32]. In order to evaluate
the therapeutic potential of SFV-IL-12 against breast
cancer, we took into consideration all these previous
experiences, and injected a relatively high dose of SFV-
IL-12 (2×108 vp) at two early stages of the disease: the
first dose was given at day 10 and the second dose was
given at day 13 after 4T1 implantation (Fig. 2). Tumor
growth was periodically measured and animals were
monitored for survival outcome. Similarly, control groups
received two i.t. doses of an SFV vector expressing β-
galactosidase (SFV-LacZ) or PBS. As shown in Fig. 2a,
treatment with SFV-IL-12 caused a significant inhibition
of tumor growth prolonged until days 20-25. At this stage,
control animals showed large ulcerated and irrigated tu-
mors, whereas SFV-IL-12 treated tumors were small and
whitish, due to a visible reduction of vasculature (Fig. 2c).
These data are consistent with the described antiangio-
genic effect of IL-12 in 4T1 tumors and in other IL-12-
treated tumor models [18, 32–35] indicating the in vivo
activity of this cytokine. The survival of SFV-IL-12
injected animals was significantly extended compared to
the SFV-LacZ and PBS control groups, although no ani-
mals showed long-term survival (Fig. 2c). Moreover, a sig-
nificant lower number of lung metastasis was observed at
day 35 in SFV-IL-12 treated mice (Fig. 2d), suggesting that
their extended survival rate may be a consequence of the
reduced metastatic burden at a time point when untreated
animals start to die. Together, these results show that
SFV-IL-12 induce a marked local antiangiogenic effect in
implanted 4T1 tumors, which may contribute to inhibit
primary tumor growth for a limited period of time, as well
as to reduce dissemination of metastasis in the organism,
prolonging consequently animal survival. However, SFV-
IL-12 monotherapy, at least at the employed dose regimen,
was insufficient to achieve complete tumor remission and
to prevent the spread of 4T1 lung metastasis.
Surgical resection of tumors after SFV-IL-12 administrations
achieves long-term survival in 20 % mice
In order to mimic frequent management of patients with
LABC, we have implemented a therapeutic protocol that
included surgical removal of primary tumors after a pre-
liminary treatment. Unlike conventional neadjuvant sys-
temic approaches, here we performed local administration
of the therapeutic agent (Fig. 3a). Two doses of SFV-IL-12
were injected inside the tumor mass at days 10 and 13
after 4T1 cells inoculation. Tumors were surgically re-
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Fig. 2 Antitumor effect of SFV-IL-12 in 4T1 tumor bearing mice. Two doses of SFV-LacZ or SFV-IL-12 (2×108 vp in 50 μl PBS) were i.t. injected at
days 10 and 13 after 4T1 cells inoculation. An equivalent volume of PBS was administered to control animals a Tumor size progression was measured every
3-6 days and mean tumor volumes were calculated for each group (n= 6). b Kaplan–Meier plot shows the survival rate of the same mice. c Pictures of
representative tumors 21 days after 4T1 cells inoculation showing the external aspect (upper panel) and interior tumor region (lower panel). A reduced
volume and vasculature was observed in treated mice compared to control mice. d An additional group of treated and control animals were sacrificed
35 days after tumor cells inoculation and 4T1 lung metastases were quantified as described in Methods. Non-significant (n.s), p< 0.01 (**); p< 0.001 (***)
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Fig. 3b, the overall survival of SFV-IL-12 treated animals
was significantly higher than that of controls. In addition,
20 % of long-term survivors were observed in the IL-12-
based neoadjuvant post-operatory setting. All of the non-
survivor animals experienced breathing difficulties before
death and showed numerous macroscopic lung metastases
as was previously observed in untreated mice (see Fig. 1c).
In contrast, mice that survived at the end of this study did
not present any visible metastasis. However, the fact that
long-term survival was only achieved in a small percentage
of treated mice indicated that our strategy to treat this type
of cancer needed to be improved. Based on several studies
that report the benefit obtained when combining IL-12-
based gene therapy with complementary strategies or drugs
[36–40], we next decided to combine SFV-IL-12 with an-
other biological agent that could collaborate in inducing a
more efficient response against the metastatic disease.
Synergistic anti-metastatic effect of combined SFV-IL-12
and Salmonella LVR01 neoadjuvant therapy achieves
long-term survival in 90 % treated mice
We hypothesized that live attenuated Salmonella could be
a good complement for IL-12-based antitumor therapydue to the intrinsic immune-stimulatory properties and
the better antitumor responses observed when admin-
istering bacteria carrying plasmids that express pro-
inflammatory cytokines (reviewed in [41]). Additionally, a
recent related study of our group has shown that i.t. ad-
ministrations of Salmonella LVR01 generate a consider-
able dose-dependent antitumor effect in a mouse model
of B-cell lymphoma [42]. Despite this result, when two
doses of LVR01 were inoculated into primary 4T1 tumors,
no survival improvement was seen in tumor-bearing ani-
mals (Fig. 4). Surgical removal of the tumor after LVR01
inoculations led to a significant death delay, although no
animals survived for the long-term (Fig. 4). In this case, all
mice died with large macroscopic lung and disseminated
metastasis, indicating that LVR01 alone was insufficient to
control the 4T1 metastatic process. Nevertheless, the in-
oculated bacteria were able to invade tumor cells and in-
duce local microscopic tissue distortion and granulocyte
infiltration (Fig. 5), persisting inside the tumor mass for
several days (see Additional file 1).
On the other hand, when SFV-IL-12 (day 10) was
combined with LVR01 administration (day 13) followed
by surgical removal of the treated tumor (day 16, Fig. 6a),
a clear synergy in the antitumor action was observed,
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Fig. 3 Neoadjuvant effect of SFV-IL-12. a Schematic representation of
the therapeutic protocol performed in this study. Two doses of SFV-LacZ,
SFV-IL-12 or PBS were i.t. injected as in Fig. 2. Three days later (i.e. day 16
after 4T1 cells inoculation), treated tumors were surgically removed
(S-16). b Kaplan–Meier plot shows the survival rate of treated and control
mice (n= 5-10). Non-significant (n.s), p< 0.001 (***)
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Fig. 4 Antitumor effect of LVR01 in 4T1 tumor bearing and tumor-
excised animals. a Schematic representation of the therapeutic
protocol performed in this study. Two doses of LVR01 (2×107 cfu in
50 μl PBS) or 50 μl PBS were i.t. injected at days 10 and 13 after 4T1
cells inoculation. In the indicated groups, the treated tumors were
surgically removed at day 16 (S-16). b Kaplan–Meier plot shows the
survival rate of treated and control mice (n = 5-9). Non-significant
(n.s); p< 0.001 (***)
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sis. However, if treated tumors were not resected, all
mice died, indicating that this combined therapy only
works in neoadjuvancy (Fig. 6b). Interestingly, we found
that the order of the injected factors dramatically af-
fected the antitumor response, since the administration
of LVR01 prior to SFV-IL-12 did not show any synergy
and all animals died at similar rate than control groups
(Fig. 6a and b). It is worth to note, that at the time of
surgery, tumors receiving only LVR01 or the ineffective
LVR01 + SFV-IL-12 combination showed a bigger size
compared to SFV-IL-12 alone or SFV-IL-12 + LVR01
treated animals (Fig. 6c). In addition, inhibition of vascu-
lature was observed with effective SFV-IL-12 + LVR01,
but not with the LVR01 + SFV-IL-12 combination (Fig. 6d).
Moreover, we found that IL-12 expression was signifi-
cantly reduced in mice receiving LVR01 prior to SFV-IL-
12 (day 14, Fig. 7a), while a higher amount of IFN-γ (a
main mediator of IL-12 activity) was induced earlier in the
effective combination (day 11, Fig. 7b), indicating that the
right levels and dynamics of both cytokines expression
may be associated with the curative effect of the combined
therapy. In this regard, we also observed a significantincrease of CD8+ and CD4+ T cells in draining lymph
nodes isolated from the effective LVR01 + SFV-IL-12 com-
bined group (see Additional file 2). Overall, these data
demonstrate that the synergic neoadjuvant action of SFV-
IL-12 and Salmonella LVR01 prevent and eradicate breast
cancer metastasis that could be disseminated in the organ-
ism before surgical removal of the tumors. Our observa-
tions point out to the importance of reducing angiogenesis
and inducing an efficient immune response at early stages
of the disease.
Re-challenged mice efficiently respond to a second
SFV-IL-12 + LVR01 neoadjuvant treatment
As shown above, surgery of primary tumors performed
16 days after 4T1 cells inoculation did not prevent lung
metastasis formation and animal death, whereas an effi-
cient long-term antitumor effect was observed after re-
ceiving the right neoadjuvant combined therapy. This
data suggests that the mice cured from metastatic dis-
ease may have developed a systemic antitumor immun-
ity, which, in theory, could protect them from a second
4T1 cells challenge. To test this hypothesis, we inocu-
lated 104 4T1 cells in the left abdominal mammary gland
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Fig. 5 Microscopic characteristics of LVR01 infected tumors. 2×107 cfu were inoculated into 4T1 tumors. Three days later, tumors were extracted,
crio-preserved and analyzed. In figures a-c LVR01 is stained in red (AntiLPS Alexa 555), DNA in blue (DAPI) and cell membranes in green (WGA 488). In
d-e, Gr1+ cells are shown in blue (Gr1-Alexa 488) and cell membranes are shown in green (WGA350). a Tumor regions without bacteria (I), or invaded with
low (II) or high (III) density of LVR01 show a dose-dependent tissue distortion effect. b Bacterial conglomerates (arrow) indicate possible intracellular
replication. c DNA staining of infected zones reveals nuclear morphologies characteristic of myeloid cells (arrows) in the proximity of LVR01 accumulation.
d Gr1+ cells are present in the proximity of bacterial infected zones d Absence of granulocytes in tumoral regions without Salmonella
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plantation (Fig. 8a). Contrary to our expectations, all of
these animals developed mammary tumors and died, al-
though with a significant slower rate than control naïve
mice that received an equal dose of 4T1 cells (Fig. 8b),
indicating that specific antitumor immunity might be
elicited. However, removal of the primary tumor at day
16 post-inoculation (performed in order to reduce tumor
cells burden in the organism) did not improve survival,
suggesting that this elicited immune response was too
weak to protect these mice from a secondary challenge.
On the other hand, treatment with SFV-IL-12 and
Salmonella LVR01, when followed by excision of the
tumor, again showed a very potent antitumoral effect,
achieving 100 % of long-term survival (Fig. 8b). These
data indicate that although the combined therapy does
not induce an efficient long-lasing protection against
4T1 tumors, it allows the use of the same treatment tocure a secondary mammary tumor in the same animal, a
situation that could be clinically relevant to treat pa-
tients who suffer from relapse.
Discussion
Neoadjuvant therapies aim to reduce the size or extent
of primary tumors before radical intervention, as well as
to eliminate early disseminated micro-metastasis in lo-
cally advanced malignancies, such as LABC [2]. In the
present study, we have evaluated the efficacy of a com-
bined neoadjuvant gene therapy approach against the
highly metastatic 4T1 mouse model, which we have cor-
related here with severe LABC type of cancers (Fig. 1).
Our neoadjuvant approach is based on the use of IL-12,
a potent immunostimulatory cytokine with strong anti-
angiogenic activity [32, 35, 43] in combination with
LVR01, an attenuated auxotrophic mutant of S. Typhi-
murium [27, 42] as co-adjuvant factor. To allow IL-12
A
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Fig. 6 Combined neoadjuvant antitumor effect of SFV-IL-12 and LVR01. One dose of SFV-IL-12 or SFV-LacZ (2×108 vp in 50 μl PBS), or LVR01
(2×107 cfu in 50 μl PBS), or 50 μl PBS was i.t. injected at days 10 and/or 13 after 4 T1 cells inoculation. In most groups, treated tumors were
surgically removed at day 16 (S-16). a Schematic representation of the therapeutic protocol for the combinations relevant to this study.
b Kaplan–Meier plot shows the survival rate of the indicated groups of mice. The total number of animals included in the SFV-IL-12 + LVR01 +
S-16 group was 31 (consecutive experiments) and the 28 survivor mice were employed in the re-challenge study presented in Fig. 8. For the
rest of the groups n = 8-10. c Tumor size was measured before surgery (day 16) and mean + SD tumor volumes were calculated for each group.
d Representative images of treated tumors excised 16 days after 4 T1 cells inoculation. p< 0.05 (*); p< 0.01 (**); p< 0.001 (***)
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based vector encoding IL-12 genes (SFV-IL-12), which
was previously shown to express IL-12 (locally and sys-
temically) upon i.t. administration [14, 28]. In this con-
struct, each IL-12 subunit (p35 and p40) is driven by an
independent SFV subgenomic promoter fused to the
SFV capsid translation enhancer achieving higher ex-
pression levels and stronger antitumor activity compared
to adenoviral vectors engineered to express IL-12 [16, 28].
SFV-based vectors have also the capability of inducing
apoptosis of infected cancer cells, allowing the release oftumor-associated antigens that could be taken up and
cross-presented by antigen-presenting cells [14, 36, 44, 45].
In addition, SFV-IL-12 achieves transgene expression
after multiple i.t. administrations and triggers efficient
antitumor immune responses in different cancer models
[14–16, 18, 28, 46]. Salmonella LVR01 was also demon-
strated to induce death of infected tumor cells and to
trigger innate and adaptive immune responses after
multiple i.t. administrations [42]. These responses are
associated to Toll-like receptors recognition of pathogen
associated molecular patterns (PAMPs) in the bacteria,
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Fig. 7 Expression of cytokines in treated mice. Blood samples were
collected the next day after administration of the combined
treatments presented in Fig. 6 (days 11 and 14) and 9 days after
surgery (day 25) and serum levels of a IL-12 and b IFN-γ were
measured by ELISA. Non-significant (n.s); p< 0.05 (*); p< 0.001 (***)
Kramer et al. BMC Cancer  (2015) 15:620 Page 10 of 15such as lipopolysaccharide (LPS), teichoic acid, peptido-
glycan, and bacterial CpG DNA [41, 47]. Although the
LVR01 bacterial strain has been extensively tested as
carrier for heterologous antigens for human and veterin-
ary vaccination applications [48–50], its use as antican-
cer agent is relatively recent [42, 51] and therefore is
still an open area for investigation. Still, the use of
Salmonella for anticancer therapies, either as monother-
apy or combined, has received extensive consideration
in the last decade, showing different degree of effectivity
in a number of animal models of major human cancer
types including breast cancer [52–58]. Particularly, a
Salmonella A1-R-based monotherapy was recently re-
ported with promising results in a 4T1 brain metastatic
model [59], although these experiments were conducted
in nude mice and long-term protection was not evaluated.In any case, to date only a few approaches using attenu-
ated strains of Salmonella have moved into initial clinical
trials and none of them have progressed into large phase
II clinical trials, paving the way for the search of alterna-
tive combined therapies.
Our data showed a clear reduction of tumor blood
supply, delay of tumor growth, lower number of lung
metastasis and a better survival in SFV-IL-12 treated
mice compared to PBS and SFV-LacZ controls. Even
though, only 20 % of animals survived long-term after
receiving one or two i.t. doses of SFV-IL-12 in the neo-
adjuvant setting, indicating that an increased dose
regimen of SFV-IL-12 monotherapy did not seem to
augment its antitumor effectiveness (Figs. 3 and 6, re-
spectively). In this regard, a previous report showed in-
hibition of primary tumor growth after 6 consecutive i.t.
injections of a similar SFV-IL-12 vector in 4T1 tumor-
bearing mice, inferring an effective antitumor response
using SFV-IL-12 alone [18]. However, these studies were
followed up only until day 22 (when mice were sacrificed
in order to measure the presence of lung metastasis), a
time period where we also observed tumor growth in-
hibition. Nevertheless, in our long-term studies, all tu-
mors recovered their growth dynamics after day 25-30
and animals died between days 50 and 65 due to meta-
static disease, indicating that IL-12 alone was efficient in
delaying tumor growth and death, but insufficient to
cure these animals. In accordance with our data, the au-
thors also observed metastasis reduction and a potent
antiangiogenic effect of SFV-IL-12 in 4T1 injected tu-
mors, a fact that may delay nutrient access to the tumor
mass and metastasis spread [18]. The antiangiogenic
contribution of IL-12 together with its immunomediated
antitumor properties were consistently studied and re-
ported previously [32, 34, 35, 43, 60], as well as its limi-
tations as a single antitumor agent [36]. For that reason,
in this work we focused on enhancing the SFV-IL-12–
based therapy by combining it with an appropriate
“therapeutic companion” in order to achieve long-term
cure, which was the main goal of the present study.
A number of different immunomodulatory factors and
tumor-specific antigens have shown synergistic effects
with IL-12-based therapies in different cancer models
[36, 60–62]. However, most of these studies were aimed
at evaluating antitumor efficacy against primary tumors,
without assessing their effects in neoadjuvancy. In this
regard, a relevant study performed in a lung alveolar
metastatic model, showed that i.t. administration of IL-
12-encapsulated biodegradable microspheres combined
with granulocyte-macrophage colony-stimulating factor
(GM-CSF), followed by surgical removal of tumors,
achieved significant post-operatory long-term survival
and reduction of metastasis in animals receiving the
combined treatment, compared to each monotherapy [37].
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Fig. 8 Re-challenge study and re-treatment assay. a Schematic representation of the performed protocols. The mice that had survived for 200 days
in the experiment described in Fig. 6 were challenged with 10.000 4T1 cells implanted in the forth left mammary fat pad (opposite to the site
where the first tumor was implanted). Ten days later tumors were already palpable and some of these animals were left without further treatment
(Sur) or underwent tumor surgery 16 days later (Sur + S-16), or received SFV-IL-12 (2×108 vp in 50 μl PBS) at day 10 and LVR01 (2×107 cfu in
50 μl PBS) at day 13 (Sur + SFV-IL-12 + LVR01), or received this last treatment followed by surgery (Sur + SFV-IL-12 + LVR01 + S-16). A healthy
and untreated group of animals with similar age were equally inoculated with 10.000 4T1 cells and left without further treatment (Control)
or underwent surgery (Control + S-16). b Kaplan–Meier plot shows the survival rate of the indicated groups of mice (n = 6-9). Survival days
were counted since the second (re-challenged) 4T1 inoculation. p< 0.01 (**); p< 0.001 (***)
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treatments could help to prevent post-operatory dissemin-
ation of the metastatic disease, and, together with other
studies, confirm that antitumor IL-12-based therapies
could benefit from combinations with other cytokines,
antibodies or chemotherapy [36–40]. We hypothesized
that live attenuated Salmonella could be a proper IL-12
co-adjuvant due to the bacterial intrinsic immune-
stimulatory and antitumor properties, its easy and
cheap high-scale production, and its enhanced thera-
peutic activity observed when transformed with plas-
mids expressing immune-stimulatory cytokines ([41]
and references therein). Recently, Grille et al, showed
an improved survival outcome in mice receiving mul-
tiple i.t. doses of Salmonella LVR01 in the A20 lymph-
oma model [42]. However, in the 4T1 breast cancer
model, we did not see any therapeutic response intumor-bearing animals treated solely with LVR01, con-
firming the previously inferred resistance of 4T1 tu-
mors to immunotherapies [13], although a significant
increase in the overall survival was achieved in neoad-
juvancy. Anyhow, we detected the infiltration of granu-
locytes to the tumor site, a relevant observation, since
it was suggested that this cell population (specially
neutrophyls) is involved in Salmonella-mediated thera-
peutic effect [42, 63]. In addition, LVR01-treated tu-
mors showed microscopic distortions, probably due to
the bacterial replication and destruction of infected
cells. It is important to remark that all 4T1 tumors
treated with LVR01 alone (either with 1 or 2 doses) expe-
rienced a significant increase in size, which is consistent
with a strong inflammatory reaction and observed vas-
cularization. Consequently, these tumors were more diffi-
cult to resect than their SFV-IL-12 counterparts, because
Kramer et al. BMC Cancer  (2015) 15:620 Page 12 of 15they got strongly attached to the peritoneum and skin bor-
ders. This fact made the evaluation of a multiple dose
regimen protocol surgically impracticable.
We discovered an impressive synergistic effect when a
single i.t. dose of SFV-IL-12 (2×108 vp given at day 10
after 4T1 cells implantation) was followed by a single i.t.
dose of LVR01 (2×107 cfu given at day 13) prior to surgi-
cal removal of the treated tumor (day 16). Here, 90-
100 % treated animals survived for a time period that
could be considered life-long in mice (total 350 days;
Figs. 6 and 8). However, to our surprise, if LVR01 was
administered before SFV-IL-12, the combined antitumor
synergy was completely lost in our neoadjuvant experi-
mental setting. The reason by which this synergy operates
or can be abolished may involve multiple mechanisms,
since the type of vector, cytokine and bacteria employed
in this study are able to trigger a diverse spectrum of ef-
fects and pathways [17, 18, 28, 42, 45] and therefore, their
relative contribution will require further investigations. So
far, and based on our data, we could mainly speculate that
i.t administration of SFV-IL-12 allow sufficient IL-12 ex-
pression to activate antiangiogenic responses contributing
to inhibit primary tumor growth, and in this favorable
context (which might converge with an adequate amount
and type of SFV-IL-12-induced immune mediators [17, 34]),
the addition of a potent adjuvant, like LVR01, can prob-
ably promote a systemic response able to eliminate dis-
seminated micro-metastases in the organism, something
that is not achieved by SFV-IL-12 or LVR01 alone. In ac-
cordance with the higher expression levels of IL-12 ob-
served in the SFV-IL12 + LVR01 vs LVR01 + SFV-IL12
treated animals, also a significantly higher production of
IFN-γ was achieved in the former group at early time
points, promoting the idea that the better therapeutic out-
come in this group could be associated to a T helper 1
primed response timely induced for which an early source
of IFN-γ is strictly required [64]. Indeed, previous studies
demonstrated that CD8+ cytotoxic T cells are major
players in antitumor responses triggered by SFV-IL-12 ei-
ther alone or combined with a proper agonist [28, 36, 46].
Consistently, we obtained initial data showing a higher
amount of CD8+ T cells in draining lymph nodes isolated
from SFV-IL-12 + LVR01 compared to LVR01 + SFV-IL-
12 treated animals. The fact that synergy is not observed
when LVR01 is given before SFV-IL-12 suggests that the
first agent is not as efficient as SFV-IL-12 to prime an
adequate microenvironment and efficient immune re-
sponses, or alternatively, that LVR01 infection could affect
posterior SFV-IL-12 tumor cells transduction. In any case,
we found that tumor pre-infection with LVR01 resulted in
a significant decrease of SFV-IL-12-mediated expression
of IL-12, which would explain the lack of IL-12-mediated
antiangiogenic effect in treated tumors, as well as the re-
duced IFN-γ levels and CD8+ T cells in these animals.Overall, our data suggest the importance of reducing
angiogenesis and inducing an efficient immune response
at early stages of the disease in order to achieve a potent
therapeutic effect.
The lack of protection against a secondary challenge
may indicate that our therapeutic procedure does not
stimulate an efficient long-lasting antitumor immunity.
Nevertheless, we found that the application of same
treatment (combined adjuvant therapy followed by surgi-
cal removal of primary tumors) is equally effective to
cure animals when used into re-challenged mice, a find-
ing that we believe could be clinically relevant to treat
patients who suffer from relapse. Thus, this combined
therapy may be worth of considering for clinical trials.
In summary, we have described a promising neoadju-
vant therapeutic strategy to treat a highly aggressive type
of breast cancer. To our knowledge, this is the first ex-
perimental protocol reported to date that combine: gene
therapy + bacteria-based therapy + surgical removal of
primary tumors, for the prevention and treatment of the
metastatic disease, and that achieved long-term curative
results in the clinically relevant 4T1 model. In addition,
we demonstrated that all re-challenged mice were able to
respond to a second neoadjuvant SFV-IL-12 + LVR01
treatment, rising further optimism about this experimen-
tal approach, since in the clinic, relapsed mammary tu-
mors are often more difficult to be therapeutically solved.
This strategy would have at least three main theoretical
advantages compared to other immuno- or chemical-
based therapies. First, the in situ administration of each
therapeutic agent would avoid, in theory, systemic toxicity.
Second, an expected locally induced immunity would spe-
cifically recognize and destroy cancer cells, thus diminish-
ing unspecific effects. Third, by combining SFV-IL-12
with Salmonella and surgery we could reduce the doses of
the viral vector, more complex to produce than bacteria,
lowering the cost of therapy. In addition, we believe that
such a strategy could be clinically feasible because: (i) ad-
ministration of alphavirus-based vectors similar to SFV,
has been already proven to be safe in phase I/II clinical tri-
als [65] (ii) live attenuated Salmonella strains have also
been assayed in clinical trials showing a good safety profile
[66] with a bacteria-based therapy successfully being used
for the treatment of patients with bladder cancer [67, 68],
(iii) neoadjuvant i.t. administration of a gene therapy vec-
tor combined with chemotherapy has been already clinic-
ally tested in LABC patients, showing to be feasible and
safe [69]. Finally, combinatorial treatments are perceived
as a major pathway for progress in cancer therapy with
a number of pre-clinical and clinical events revealing
synergistic antitumor activities. It is therefore encouraging
to anticipate that combined biological approaches could
become interesting options for the treatment of malignan-
cies that lack cure in the present.
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We have correlated the metastatic 4T1 model with severe
cases of locally advanced breast cancer in the clinic. In
addition, we found that mice that underwent surgery of
primary tumors 16 days after 4T1 cells inoculation could
represent a good model for minimal residual disease, since
at this time-point 100 % animals presented lung micro-
metastasis which progressed until causing death in all
animals. Aiming to find an effective treatment against
metastatic breast cancer, we have developed a novel
approach based on the combined intratumoral adminis-
tration of a SFV vector expressing interleukin-12 (SFV-IL-
12) and attenuated Salmonella LVR01 followed by surgical
removal of the treated primary tumors. This neoadjuvant
combined therapy was markedly synergistic compared to
each treatment alone and its efficacy depended on the
order in which both factors were administered. We
achieved 90 % long-term survival only when SFV-IL-12
was administered previous to LVR01, whereas admin-
istration of LVR01 before SFV-IL-12 did not have any
antitumor activity. Our observations point out to the im-
portance of reducing tumor angiogenesis and inducing an
efficient immune response at early stages of primary
tumor establishment in order to prevent and/or eradicate
disseminated 4T1 metastasis before surgical intervention.
These antitumor effects were associated to early and suffi-
cient IL-12 and INF-γ expression levels induced by SFV-
IL-12 inoculation. We also found that, although the
combined therapy does not induce an efficient long-term
protection against 4T1 tumors, 100 % of re-challenged
mice could be totally cured by applying the same neoadju-
vant combined regimen. These data increase the clinical
relevance of this experimental approach, since it could be
applicable to patients who suffer from relapse. In addition,
this study may provide new opportunities to evaluate such
a biological therapy against a number of other aggressive
and metastatic types of cancers.Additional files
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